4
ALL4
Sinopia BiosciencesYear
4
ALL2
20242
2023DEALS // DEV.
4
ALL4
DealsCountry
4
ALL4
U.S.A4
ALL1
Michael J. Fox Foundation for Parkinson’s Research1
NIDCR1
National Institute of General Medical Sciences1
National Institute of Neurological Disorders and StrokeTherapeutic Area
4
ALL1
Gastroenterology2
Neurology1
OncologyStudy Phase
4
ALL2
Preclinical1
Discovery Platform1
DiscoveryDeal Type
4
ALL4
FundingProduct Type
4
ALL2
Other Small Molecule2
UndisclosedDosage Form
4
ALL1
Oral3
UndisclosedLead Product
4
ALL2
SB-01102
UndisclosedTarget
4
ALL4
UndisclosedLead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : NIDCR
Deal Size : $2.2 million
Deal Type : Funding
Sinopia Gets SBIR Phase II Grant For Oral Mucositis Research
Details : The funding aims to support the company in discovering novel small molecules and identifying promising treatment candidates for oral mucositis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : NIDCR
Deal Size : $2.2 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : National Institute of General Medical Sciences
Deal Size : Undisclosed
Deal Type : Funding
Sinopia Secures Grant from NIGMS to Advance Metabolomics Platform
Details : The proceeds will advance its computational drug discovery LEarn And DiScover (LEADS™) platform and explore applications in oncology and immunology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : National Institute of General Medical Sciences
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : $2.0 million
Deal Type : Funding
Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase I clinical trials.
Product Name : SB-0110
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 19, 2023
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : $2.0 million
Deal Type : Funding
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Institute of Neurological Disorders and Stroke
Deal Size : $3.3 million
Deal Type : Funding
Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase II clinical trials.
Product Name : SB-0110
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 19, 2023
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Institute of Neurological Disorders and Stroke
Deal Size : $3.3 million
Deal Type : Funding